Ultragenyx Pharmaceutical (RARE) Price & Analysis

Compare

1,090 Followers

RARE Stock Chart & Stats

$34.58

-$0.60(-1.35%)

At close: Jan 08 4:00 PM EST

$34.58

-$0.60(-1.35%)

Day’s Range― - ―

52-Week Range$25.81 - $46.50

Previous CloseN/A

Volume75.38K

Average Volume (3M)1.41M

Market Cap

$3.29B

Enterprise Value$3.44B

Total Cash (Recent Filing)$425.25M

Total Debt (Recent Filing)$863.11M

Price to Earnings (P/E)―

Beta0.98

Next Earnings

Feb 12, 2026

EPS Estimate

-1.17

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.81

Shares Outstanding96,477,570

10 Day Avg. Volume1,674,685

30 Day Avg. Volume1,408,859

Financial Highlights & Ratios

PEG Ratio0.28

Price to Book (P/B)14.92

Price to Sales (P/S)6.80

P/FCF Ratio-9.03

Enterprise Value/Market Cap1.04

Enterprise Value/Revenue5.45

Enterprise Value/Gross Profit6.43

Enterprise Value/Ebitda-7.11

Forecast

1Y Price Target

$76.31

Price Target Upside120.68% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering14

EPS Forecast (FY)-5.65

Revenue Forecast (FY)$655.90M

Bulls Say, Bears Say

Bulls Say

Funding StrategyThe OMERS deal is seen as a creative strategy to bring in additional funding without dilution.

Product Launch ReadinessRARE strengthened liquidity with $400M non-dilutive financing from OMERS, deferring payments until 2028 to support launch readiness and maintain its path to profitability in 2027.

Revenue GuidanceManagement reiterated the FY25 total revenue guidance range which remains $640M-$670M.

Bears Say

Earnings PerformanceRARE reported a 3Q25 GAAP EPS of $(1.81), which compared unfavorably to consensus estimates.

Revenue MissThe 3Q25 total revenue of $160M missed versus consensus estimates.

Stock Price ReactionThe stock was down 17% after hours in response to the news.

Ultragenyx Pharmaceutical News

Ultragenyx price target lowered to $50 from $81 at Barclays

Barclays analyst Gena Wang lowered the firm’s price target on Ultragenyx (RARE) to $50 from $81 and keeps...

1M ago

RARE

Ultragenyx (RARE) Earnings Call Highlights Growth and Challenges

Ultragenyx Pharmaceutical, Inc. (($RARE)) has held its Q3 earnings call. Read on for the main highlights of the...

2M ago

RARE

Ultragenyx Pharmaceutical Positioned for Success with Strategic Financing and Promising Setrusumab Trials

Morgan Stanley analyst Maxwell Skor maintained a Buy rating on Ultragenyx Pharmaceutical today and set a price target...

2M ago

RARE

Positive Outlook for Ultragenyx Pharmaceutical: Buy Rating Affirmed Amid Financial Strength and Product Growth

William Blair analyst Sami Corwin has maintained their bullish stance on RARE stock, giving a Buy rating today....

2M ago

RARE

Ultragenyx price target lowered to $75 from $86 at TD Cowen

TD Cowen lowered the firm’s price target on Ultragenyx (RARE) to $75 from $86 and keeps a Buy...

2M ago

RARE

Ultragenyx Reports Q3 2025 Financial Results

Ultragenyx Pharmaceutical, Inc. ( ($RARE) ) has released its Q3 earnings. Here is a breakdown of the information...

2M ago

RARE

Closing Bell Movers: AMD falls 4% on earnings, Trex, Pinterest down sharply

The opening hour of the evening session is seeing the continuation of investor sentiment souring on high-flying Tech...

2M ago

Ultragenyx sells additional 25% of Crysvita royalty interest for $400M

Ultragenyx (RARE) announced the sale, for $400M, of an additional 25% of the company’s royalty interest from Kyowa...

2M ago

RARE

Ultragenyx Signs $400M Royalty Purchase Agreement

Ultragenyx Pharmaceutical ( ($RARE) ) just unveiled an announcement. On November 3, 2025, Ultragenyx Pharmaceutical entered into a...

2M ago

RARE

Ultragenyx reports Q3 EPS ($1.81), consensus ($1.21)

Reports Q3 revenue $159.9M, consensus $166.79M. The company said, “We announced today that we bolstered our balance sheet...

2M ago

RARE

Ultragenyx affirms 2025 revenue outlook $640M-$670M, consensus $657.39M

Ultragenyx (RARE) also reaffirmed its net cash used in operations guidance for 2025, which is expected to modestly...

2M ago

RARE

RARE Upcoming Earnings Report: What to Expect?

Ultragenyx Pharmaceutical, Inc. (RARE) is scheduled to report 3rd quarter earnings on 11/04/2025, after the market closes. Regarding...

2M ago

RARE

Ultragenyx Begins Dosing in Aurora Study for Angelman Syndrome

Ultragenyx Pharmaceutical ( ($RARE) ) just unveiled an update. On October 30, 2025, Ultragenyx Pharmaceutical announced the dosing...

2M ago

RARE

Ultragenyx announces first patient dosed in Aurora study

Ultragenyx (RARE) Pharmaceutical announced that the first patient has been dosed in the Aurora study evaluating the efficacy...

2M ago

RARE

RARE FAQ

What was Ultragenyx Pharmaceutical, Inc.’s price range in the past 12 months?

Ultragenyx Pharmaceutical, Inc. lowest stock price was $25.81 and its highest was $46.50 in the past 12 months.

What is Ultragenyx Pharmaceutical, Inc.’s market cap?

Ultragenyx Pharmaceutical, Inc.’s market cap is $3.29B.

When is Ultragenyx Pharmaceutical, Inc.’s upcoming earnings report date?

Ultragenyx Pharmaceutical, Inc.’s upcoming earnings report date is Feb 12, 2026 which is in 47 days.

How were Ultragenyx Pharmaceutical, Inc.’s earnings last quarter?

Ultragenyx Pharmaceutical, Inc. released its earnings results on Nov 04, 2025. The company reported -$1.81 earnings per share for the quarter, missing the consensus estimate of -$1.234 by -$0.576.

Is Ultragenyx Pharmaceutical, Inc. overvalued?

According to Wall Street analysts Ultragenyx Pharmaceutical, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Ultragenyx Pharmaceutical, Inc. pay dividends?

Ultragenyx Pharmaceutical, Inc. does not currently pay dividends.

What is Ultragenyx Pharmaceutical, Inc.’s EPS estimate?

Ultragenyx Pharmaceutical, Inc.’s EPS estimate is -1.17.

How many shares outstanding does Ultragenyx Pharmaceutical, Inc. have?

Ultragenyx Pharmaceutical, Inc. has 96,477,570 shares outstanding.

What happened to Ultragenyx Pharmaceutical, Inc.’s price movement after its last earnings report?

Ultragenyx Pharmaceutical, Inc. reported an EPS of -$1.81 in its last earnings report, missing expectations of -$1.234. Following the earnings report the stock price went down -1.818%.

Which hedge fund is a major shareholder of Ultragenyx Pharmaceutical, Inc.?

Currently, no hedge funds are holding shares in RARE

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Ultragenyx Pharmaceutical Stock Smart Score

Underperform

Fundamentals

Return on Equity

-325.76%

Trailing 12-Months

Asset Growth

-22.62%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Ultragenyx Pharmaceutical, Inc.

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.

Ultragenyx Pharmaceutical (RARE) Earnings & Revenues

Historic Earnings Reports

RARE Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call reflected a positive outlook due to strong financial positioning, consistent revenue growth, and promising pipeline advancements, despite challenges such as net losses and regulatory hurdles.View all RARE earnings summaries

RARE Stock 12 Month Forecast

Average Price Target

$76.31

▲(120.68% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"27":"$27","74":"$74","121":"$121","50.5":"$50.5","97.5":"$97.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":120,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$120.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":76.31,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$76.31</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$35.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[27,50.5,74,97.5,121],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.37,40.03384615384615,46.69769230769231,53.36153846153846,60.02538461538461,66.68923076923076,73.35307692307691,80.01692307692306,86.68076923076922,93.34461538461537,100.00846153846152,106.67230769230767,113.33615384615385,{"y":120,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.37,36.67307692307692,39.97615384615384,43.279230769230765,46.582307692307694,49.88538461538461,53.18846153846154,56.49153846153846,59.79461538461538,63.097692307692306,66.40076923076923,69.70384615384614,73.00692307692307,{"y":76.31,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.37,33.495384615384616,33.62076923076923,33.746153846153845,33.87153846153846,33.996923076923075,34.12230769230769,34.247692307692304,34.37307692307692,34.49846153846154,34.62384615384615,34.74923076923077,34.87461538461538,{"y":35,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":47.6,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.07,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.03,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.92,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.84,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.97,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.14,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.26,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.44,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.03,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.99,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.6,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.37,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >